Phamacology Chapter 11 Pharmacotherapy Of The Pediatric Patient

Front 1

adherence

Back 1

taking medications in the manner prescribed by the health care provider, or in the case of OTC drugs, following the instructions on the label; also called compliance

Front 2

Best Pharmaceuticals for Children Act

Back 2

authorizes the FDA to contract for the testing of already approved pediatric drugs, or when the pharmaceutical company declines the option of exclusivity

Front 3

blood-brain barrier

Back 3

anatomic structure that inhibits many chemicals and drugs from gaining access to the brain

Front 4

body surface area (BSA) method

Back 4

method of calculating pediatric dosages using an estimate of the child's BSA

Front 5

body weight method

Back 5

method of calculating pediatric dosages which requires a calculation of the number of milligrams of drug, based on the child's weight in kilograms (mg/kg)

Front 6

directly observed therapy (DOT)

Back 6

requires that a health care provider directly observe the patient swallowing the pills, whether it is in the hospital, office, or home care setting

Front 7

Food and Drug Administration (FDA) Modernization Act

Back 7

gave financial incentives for pharmaceutical companies to conduct pediatric research in pharmacology; in exchange for providing pediatric labeling, the legislation gives drug companies the ability to exclusively market the drug for 6 months with no competition

Front 8

nomogram

Back 8

a representation by graphs, diagrams, or charts of the relationship between numerical variables; used for drug calculations

Front 9

Pediatric Research Equity Act of 2003

Back 9

authorizes the FDA to require research of pediatric uses for new drugs